VUSION
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- VUSION
- Generic name
- MICONAZOLE NITRATE, ZINC OXIDE, WHITE PETROLATUM
- Manufacturer
- Mylan Pharmaceuticals Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- b026bc7d-3a18-41e8-88c4-1e063cd2f42c
- SPL ID
- 1b5de1cf-d19f-424b-86c0-e2ebcb0b3cf0
- Version
- 3
- Effective date
- 2018-08-14
- Source export date
- 2026-09-28
- Source partition
- 7
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/bb1af06e95bcf9567b07e56fcf3a03c0cac3c7c82ff89d4c970881174949e5b7/drug-label-0007-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 05:47:56
| Harmonized routes |
|---|
| TOPICAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | NDA | 021026 | derived:openfda.application_number |
| application number | NDA021026 | openfda.application_number | |
| brand name | VUSION | openfda.brand_name | |
| generic name | MICONAZOLE NITRATE, ZINC OXIDE, WHITE PETROLATUM | openfda.generic_name | |
| manufacturer name | Mylan Pharmaceuticals Inc. | openfda.manufacturer_name | |
| ndc | package | 0378-8222-50 | openfda.package_ndc |
| ndc | product | 0378-8222 | openfda.product_ndc |
| ndc11 | package | 00378822250 | derived:openfda.package_ndc |
| rxcui | 831393 | openfda.rxcui | |
| rxcui | 831391 | openfda.rxcui | |
| spl id | 1b5de1cf-d19f-424b-86c0-e2ebcb0b3cf0 | id | |
| spl set id | b026bc7d-3a18-41e8-88c4-1e063cd2f42c | set_id | |
| unii | VW4H1CYW1K | openfda.unii | |
| unii | 4T6H12BN9U | openfda.unii | |
| unii | SOI2LOH54Z | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS • If irritation occurs or if the disease worsens, discontinue use of the medication, and contact the health care provider. ( 5.1 ) 5.1 Skin Irritation If irritation occurs or if the disease worsens, discontinue use of the medication, and contact the health care provider.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rate observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. A total of 835 infants and young children were evaluated in the clinical development program. Of 418 subjects in the miconazole nitrate, zinc oxide and white petrolatum ointment group, 58 (14%) reported one or more adverse events. Of 417 subjects in the zinc oxide/white petrolatum control group, 85 (20%) reported one or more adverse events. Adverse events that occurred at a rate of ≥ 1% for subjects who were treated with miconazole nitrate, zinc oxide and white petrolatum ointment were approximately the same in type and frequency as for subjects who were treated with zinc oxide/white petrolatum ointment. 6.2 Post-marketing Experience The following adverse reactions have been identified during post approval use of miconazole nitrate, zinc oxide and white petrolatum ointment. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Gastrointestinal Disorders: vomiting General Disorders and Administration Site Conditions: burning sensation, condition aggravated, inflammation, pain Injury, Poisoning and Procedural Complications: accidental exposure Skin and Subcutaneous Tissue Disorders: blister, dermatitis contact, diaper dermatitis, dry skin, erythema, pruritus, rash, skin exfoliation
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.